Fremanezumab (TEV-48125) 是一种人源化 IgG2a 单克隆抗体，可选择性且有效地与降钙素基因相关肽 (CGRP) 结合。CGRP 是一种 37 个氨基酸的神经肽，参与偏头痛的中枢和外周病理生理事件。Fremanezumab 具有用于慢性偏头痛研究的潜力。
| 生物活性 | Fremanezumab (TEV-48125) is a humanizedIgG2amonoclonal antibody that selectively and potently binds tocalcitoningene-related peptide (CGRP). CGRP is a 37-amino acid neuropeptide involved in central and peripheral pathophysiological events of migraine. Fremanezumab has the potential for chronic migraine research[1]. |
| Clinical Trial | |
| 性状 | |
| CAS 号 | |
| 储存方式 | Please store the product under the recommended conditions in the Certificate of Analysis. |
